Increased IL-10 in the serum of animals treated with CAR-NK-92 cells may have contributed to the better anti-AML activity in the peripheral blood as compared to mice that received the Δ-CAR-NK-92 cells. This evidence concerns the gene IL10 and acute myeloid leukemia.